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Cystic echinococcosis (CE) is a cosmopolitan zoonosis caused by the larval cystic stage of the dog tapeworm Echinococcus
granulosus. This complex multicellular pathogen produces various antigens which modulate the host immune response and
promote parasite survival and development. The recent application of modern molecular and immunological approaches has
revealed novel insights on the nature of the immune responses generated during the course of a hydatid infection, although many
aspectsoftheEchinococcus-hostinterplayremainunexplored.Thispapersummarizesrecentdevelopmentsinourunderstandingof
theimmunologyanddiagnosisofechinococcosis,indicatesareaswhereinformationislacking,andsuggestspossiblenewstrategies
to improve serodiagnosis for practical application.
1.Introduction
Two neglected parasitic diseases, of both medical and
public health importance, are cystic echinococcosis (CE)
and alveolar echinococcosis (AE), caused by Echinococcus
granulosus (Eg) and E. multilocularis, respectively. CE is a
near-cosmopolitan zoonosis and responsible for most of
the burden of echinococcosis globally [1], although AE is
endemic in Europe [2, 3] and is problematic in China [4–6].
The immunology and serodiagnosis of echinococcosis
have been reviewed previously [7–10]. In this review, we
summarize the general consensus of the immunology and
immunodiagnosis of CE, and reinforce previous ﬁndings
with observations from some recent studies.
The Echinococcus organisms have a complex life cycle
involving two hosts, a deﬁnitive carnivore host and an inter-
mediate herbivore host. Intermediate hosts become infected
by ingesting the parasite’s eggs, which are released in the
faeces of deﬁnitive hosts. The eggs hatch in the gastrointesti-
nal tract and become activated larvae which penetrate the
intestinal wall and enter the bloodstream, eventually locating
in internal organs where they develop into hydatid cysts.
Hydatid cysts of E. granulosus develop in internal organs
of humans and intermediate hosts (herbivores such as sheep,
horses, cattle, pigs, goats, and camels) as unilocular ﬂuid-
ﬁlled bladders. These consist of two parasite-derived layers,
an inner nucleated germinal layer and an outer acellular
laminated layer surrounded by a host-produced ﬁbrous
capsule as the consequence of the host immune response
[10]. Brood capsules and protoscoleces bud oﬀ from the
germinal membrane. Carnivores such as dogs, wolves, and
foxes act as deﬁnitive hosts. Sexual maturity of adult E.
granulosus occurs in the host’s small intestine within 4 to
5 weeks of ingesting oﬀal containing viable protoscoleces.
Gravid proglottids or released eggs are shed in the feces. An
intermediate host is infected by taking an egg or eggs orally.
The intermediate host produces a signiﬁcant immune
response against E. granulosus infection [10]. However, the
parasite has developed highly eﬀective strategies for escaping
the host defences and to avoid clearance. These mechanisms
can be classiﬁed as antigenic mimicry, antigenic depletion,
antigenicvariation,immunologicindiﬀerence,immunologic
diversion, and immunologic subversion [10]. Understanding
how these immune responses are produced has been of2 Clinical and Developmental Immunology
fundamental importance in developing immunodiagnostic
kits and highly eﬀective recombinant vaccines against E.
granulosus infection.
There are three signiﬁcant features of E. granulosus
infection: (1) the parasite uses a large number of diﬀerent
mammalian species as intermediate hosts. Additional species
can become quickly adapted as new intermediate hosts
with the production of highly fertile cysts. Examples are
Australianmarsupials,whichhavebecomehighlysusceptible
to CE after E. granulosus was introduced into Australia at the
timeofEuropeansettlement[11],andnowplaysamajorrole
in the transmission of CE on this continent [12, 13]. (2) The
resulting chronic cyst-forming disease in the intermediate
hostischaracterizedbylong-termgrowthofthemetacestode
(hydatid) cysts in internal organs for as long as 53 years [14].
(3) The unilocular ﬂuid-ﬁlled cysts can be located in most
organs, with about 70% found in the liver, 20% occur in the
lungs, with the remainder involving other organs such as the
kidney,spleen,brain,heart,andbone.Thesedistinctfeatures
combinedwiththemulticellularnatureofE.granulosusmake
CE a good general model for studying the immunology of
chronic infections.
Cysts of E. granulosus can grow to more than 20cm
in diameter in humans, but the clinical manifestations are
generally mild and remain asymptomatic for a considerable
period. Consequently, serodiagnostic tools are important for
screening populations at high risk of infection.
2. HostImmuneResponsestoHydatidInfection
2.1.AntibodyResponses. Theearliestimmunoglobulin(Ig)G
response to CE hydatid cyst ﬂuid and oncospheral antigens
appears after 2 and 11 weeks, respectively, in mice and
sheep challenged with eggs or oncospheres of E. granulosus
[15, 16]. These antioncospheral antibodies play a major
role in parasite killing and are central to the protective
immune response against E. granulosus [17]. Although
antibody levels against the oncosphere are low [15] in the
early stages of infection, the parasite killing mechanisms
may involve antibody-dependent cell-mediated cytotoxicity
reactions [18, 19].
In the chronic phases of CE, there is frequent occurrence
of elevated antibody levels, particularly IgG, IgM, and IgE
[20–24], with IgG1 and IgG4 IgG subclasses being predom-
inant [21, 25–29]. This antibody production is essential for
the development of serodiagnostic tests.
About 30–40% of patients are antibody-negative for CE.
In many of these patients, however, varying levels of cir-
culating antigens (CAg) and circulating immune complexes
(CIC)aremeasurable[30].ThisphenomenonsuggeststhatB
cell activity and proliferation may be regulated and inhibited
by E. granulosus antigens. It is not known whether these
antigens directly target B cells or via T cell regulatory mecha-
nisms.
2.2. Cellular Responses and Th2 Regulation. During the early
stages of an echinococcal infection, there is a marked acti-
vation of cell-mediated immunity including cellular inﬂam-
matory responses and pathological changes [10, 31]. Cellular
inﬁltration of eosinophils, neutrophils, macrophages, and
ﬁ b r o c y t e so c c u r si nh u m a n s[ 32, 33] and sheep [34]
infections. However, this generally does not result in a severe
inﬂammatory response, and aged cysts tend to become sur-
rounded by a ﬁbrous layer that separates the laminated cystic
layer from host tissue.
There are very few reports on T cell cytokine proﬁles in
an early primary (oral challenge with eggs) E. granulosus
infection. Infection with E. multilocularis eggs induced low
levels of interferon- (IFN-) gama, IL-2, and IL-4 at the
beginning and high levels at the end of the infection [35,
36], and a similar immune proﬁle in the early stage of CE
infection is likely.
Given the recent advances in understanding the immun-
oregulatory capabilities of helminthic infections, it has been
suggested that Th2 responses play a crucial role in chronic
helminthiasis [37]. However, a remarkable feature of chronic
CE infection is the coexistence of IFN-gamma, IL-4 and IL-
10 at high levels in human echinococcosis [38]. It is unclear
why hydatid infection can induce high levels of both Th1
and Th2 cytokines [39] since they usually downregulate each
other [40]. Antigen and the amount of antigens released
may play key roles. For instance, E. granulosus antigen B
skewed Th1/Th2 cytokine ratios towards a preferentially
immunopathology-associated Th2 polarization, predomi-
nantly in patients with progressive disease [41].
The role of IL-10 in chronic infection largely remains
unclear, although one report showed that IL-10 may impair
the Th1 protective response and allow the parasite to
survive in hydatid patients [42]. The interaction of the
Echinococcus organisms with their mammalian hosts may
provide a highly suitable model to address some of the
fundamental questions remaining such as the molecular
basis underpinning the diﬀerent eﬀects of IL-10 on diﬀerent
celltypes,themechanismsofregulationofIL-10production,
the inhibitory role of IL-10 on monocyte/macrophage and
CD4 T cell function, its involvement in stimulating the
development of B cells and CD8 T cells, and its role in the
diﬀerentiation and function of T regulatory cells.
2.2.1. Correlation of Cytokines with Antibody Production.
Studies with mouse models to overexpress cytokines by
inducing cytokine expression vectors showed that IL-12 and
IFN-gamma induce a parasite-speciﬁc IgG2a response in
mice infected with protoscoleces of E. granulosus whereas
in IL-4-gene-transfected mice, IgG1 was elevated, indicating
that IgG1 and IgG2 antibody isotypes are regulated by Th1
and Th2 cytokines, respectively [43].
When patients with relapsing disease or with viable,
growing cysts, IgG1 and IgG4 are elevated and maintained
at a high level [21, 44], whereas a low level of IFN-gamma
produced by peripheral blood mononucleocytes (PBMC)
in vitro compared with patients with a primary infection
[45, 46]. For some relapsed cases, IFN-gamma levels were
undetectable in the sera of patients [47] whereas the
concentrations of speciﬁc IgG1 and IgG4 declined in cases
characterized by cyst inﬁltration or calciﬁcation [44].This
indicates that the IgG4 antibody response is also associated
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whereas IgG1, IgG2, and IgG3 responses occur predomi-
nantly when cysts became inﬁltrated or are destroyed by the
host [21].
2.2.2. T Cell Proﬁle, Cyst Progression, and Eﬃcacy of Treat-
ment. The polarized Th2 cell response is a signiﬁcant feature
of the chronic stage of Echinococcus infection which is
modulatedbythedevelopmentalstatusofthehydatidcyst.In
vitro T cell stimulation showed that cell lines from a patient
with an inactive cyst had a Th1 proﬁle while the T-cell lines
derived from patients with active and transitional hydatid
cysts had mixed Th1/Th2 and Th0 clones [48]. When CE
patients were drug-treated with albendazole/mebendazole,
a Th1 cytokine proﬁle, rather than a Th2 proﬁle, typically
dominated, indicating that Th1 responses have a role in the
process of cyst degeneration [46].
Mice injected with a vector expressing IL-4 displayed
six times higher cyst load than the load in control mice
[43], indicating IL-4 plays an important role in hydatid cyst
development in the mammalian host.
Cytokine analysis of 177 CE patients showed that Th1
cytokines were related to disease resistance; in contrast Th2
cytokines were associated with disease susceptibility and
chronicity [38]. Both in vitro and in vivo studies have shown
that high levels of the Th1 cytokine IFN-gamma were found
in patients who responded to chemotherapy, whereas high
levels of Th2 cytokines (IL-4 and IL-10) occurred in patients
who did not [46, 49–51], indicating IL-10/IL-4 impairs the
Th1 resistant response allowing E. granulosus to survive
[42, 52].
Self-cure of CE is common in sheep [53], and it most
likely also happens in human populations in hyperendemic
areas as patients with calciﬁed cysts are reported [54, 55].
It would be of value to consider the T cell proﬁles of these
self-cure patients as this may impact on future treatment
approaches and vaccine development.
2.2.3.DendriticCells. Morestudieshavefocusedondentritic
cells (DC) and their regulation on other immune responses
in CE. E. granulosus antigens inﬂuence maturation and dif-
ferentiation of DC stimulated with lipopolysaccharide (LPS)
[56]. This includes downmodulation of CD1a expression
and upregulation of CD86 expression, a lower percentage of
CD83(+) cells present and, downregulation of interleukin-
12p70 (IL-12p70) and TNF alpha [57]. In addition, hydatid
cyst ﬂuid (HCF) modulates the transition of human mono-
cytes to DC, impairs secretion of IL-12, IL-6, or PGE2 in
response to LPS stimulation, and modulates the phenotype
ofcellsgeneratedduringculture,resultinginincreasedCD14
expression [56].
HCF antigen B (AgB) has been shown to induce IL-1
receptor-associated kinase phosphorylation and activate
nuclear factor-kappa B, suggesting that Toll-like receptors
could participate in E. granulosus-stimulated DC maturation
[57].
E.multilocularisinfectioninmiceinducedDCexpressing
high levels TGF and very low levels of IL-10 and IL-12,
and the expression of the surface markers CD80, CD86,
and CD40 was downregulated [58, 59]. However, the higher
level of IL-4 than IFN-gamma/IL-2 mRNA expression in AE-
CD4+pe-Tcells indicated DC play a role in the generation of
a regulatory immune response [59].
Diﬀerent E. multilocularis antigens have been shown to
stimulate diﬀerent expression proﬁles of DC. Em14-3-3-
antigen induced CD80, CD86, and MHC class II surface
expression, but Em2(G11) failed to do so. Similarly, LPS
and Em14-3-3 yielded elevated IL-12, TNF-I+/−, and IL-10
expression levels, while Em2(G11) did not. The proliferation
of bone marrow DC isolated from AE-diseased mice was
abrogated [60], indicating the E. multilocularis infection
triggered unresponsiveness in T cells.
2.2.4. Summary of Immunological Responses in Echinococ-
cosis and Directions for Further Study. Human helminth
infections exhibit many immune downregulatory charac-
teristics, with aﬀected populations showing lower levels of
immunopathological disease in cohort studies of allergy
and autoimmunity. Model system studies have linked
helminth infections with marked expansion of populations
of immunoregulatory cells, such as alternatively activated
macrophages, T regulatory cells (Tregs), and regulatory B
cells [37].
In the established Echinococcus cystic stage, the typical
response, in both humans and animals, is of the Th2 type
and involves the cytokines IL-4, IL-5, IL-10, and IL-13,
the antibody isotypes IgG1, IgG4, and IgE, and expanded
populations of eosinophils, mast cells, and alternatively
activated macrophages [10, 31]. The precise role of Th2
responses in parasitic infections is still not very clear. It is
likely that E. granulosus controls the dialogue between cells
of the immune system through the release of antigens which
induce Th2 responses and suppression of others involving
regulatory T and B cells. Th2 is signiﬁcantly associated with
chronic infection and may regulate the establishment of the
parasite infection. More details are needed of the regulation
of Th2 cytokines on antibody production, echinococcal
cyst growth, and the eﬃcacy of treatment. The role of
the antibody responses in the host parasite interaction and
chronic infection remains unknown in CE.
It has been shown that in vivo depletion of DC inhibits
theinductionofaTh2immuneresponseinchronichelminth
infection and DC alone can drive Th2 cell diﬀerentiation
[37]. It is not known which DC signals induce the Th2
diﬀerentiation programme in na¨ ıve T cells [61]b u tC E
represents a good model to address this issue.
As well, a number of other critical questions remain that
areimportantforstudyingtheroleofTregcellsinthechronic
infection resulting from echinococcosis such as whether
Treg cells present in greater frequencies in echinococcal
infections as other infections [62, 63], whether Echinococcus
can expand T reg cell populations, and whether the parasites
secrete factors which can directly induce the conversion
of na¨ ıve T cells into functional Treg cells. There are no
studies in echinococcosis on regulatory B cells, which are
populations of B cells that downregulate immune responses.
These cells are most often associated with production of the
immunosuppressive cytokine IL-10.4 Clinical and Developmental Immunology
Moreover, many allergic and autoimmune inﬂammatory
conditions can be ameliorated by a range of diﬀerent
helminth infections [64–66], so the question arises: can
echinococcal infection reduce the allergic condition?
3.SerologicalDiagnosis
Typical asymptomatic features in the early stages of infection
and for a long period after establishment makes early
diagnosis of echinococcosis in humans diﬃcult. Physical
imaging to diagnose the CE infection, is usually used in the
late stages of infection. Early diagnosis of CE by serology
may,therefore,provideopportunitiesforearlytreatmentand
more eﬀective chemotherapy. Another practical application
of serology in human echinococcosis is the followup of the
treatment.
Although hydatid disease is an asymptomatic infection,
the host does produce detectable humoral and cellular re-
sponsesagainsttheinfection.Measurementoftheserespons-
es is a prerequisite for developing eﬀective serodiagnostic
tools.
3.1. Antibody Detection. Infection with larval cysts of
Echinococcus in humans and intermediate animal hosts
resultsinaspeciﬁcantibodyresponse,mainlyoftheIgGclass
accompanied by detectable IgM, IgA, and IgE antibodies in
some patients [9, 31, 76, 77].
In terms of methodology, almost all serological tests
developed for immunodiagnosis of human CE cases have
incorporated the detection of antibodies. There are con-
siderable diﬀerences between the various tests both in
speciﬁcityandsensitivity.Asthesensitivityofatestincreases,
so generally does the demand for improved antigens in
order that suﬃcient speciﬁcity can be achieved to take
advantage of the greater sensitivity. An optimum test should
be speciﬁc with high sensitivity. Insensitive and nonspeciﬁc
assays including the Cassoni intradermal test, the comple-
ment ﬁxation test (CFT), the indirect haemagglutination
(IHA) test, and the latex agglutination (LA) test have
been replaced by the enzyme-linked immunosorbent assay
(ELISA), the indirect immunoﬂuorescence antibody test
(IFAT), immunoelectrophorosis (IEP), and immunoblotting
(IB) in routine laboratory application [78].
A comparison of the diagnostic sensitivity and speciﬁcity
of IEP, ELISA, and IB, in detecting IgG antibodies in
patient sera to native and recombinant AgB and a hydatid
ﬂuid fraction (HFF), showed that HFF-IB gave the high-
est sensitivity (80%) followed by ELISA (72%) and IEP
(31%). The diagnostic sensitivity signiﬁcantly decreased as
cysts matured (from type I-II to type VII, classiﬁed by
ultrasound).Recombinantand native AgB-IByielded similar
levels of sensitivity (74%) but a large number of clinically
or surgically conﬁrmed CE patients (20%) were negative.
In these patient sera, IB, to assess the usefulness of another
recombinant E. granulosus molecule (elongation factor-1
beta/delta) in detecting IgE antibodies, yielded a positivity
of 33%. Serological tests developed for determining anti-
EchinococcusIgEinserumusuallyexpressresultsqualitatively
or semiquantitatively in titres or units speciﬁc for the test kit
[20, 79, 80].
The serodiagnostic performance of a range of diﬀerent
antigens and the various methods available for immunodi-
agnosis have been reviewed in depth [10, 31]. Some recent
studies are referred to in Table 1 with the sensitivity and
speciﬁcity of individual tests listed. Some antigens, such as
native AgB and its recombinant proteins, yielded reasonable
diagnostic performance using panels of sera from clinically
conﬁrmed cases of echinococcosis and other helminth infec-
tions. However, when the antigens were used for screening
human populations in hyperendemic communities, they
showed high seropositivity rates, although these rates had a
low correlation with US monitoring of individual subjects
[81].
Recently developed dipstick assays [82] are considered
to be valuable methods for CE serodiagnosis. One dipstick
assay has been developed that exhibited 100% sensitivity and
91.4% speciﬁcity when tested on sera from 26 CE patients
and sera from 35 subjects with other parasitic infections
using camel hydatid cyst ﬂuid as antigen [83]. Since the
dipstick assay is extremely easy to perform with a visually
interpretable result within 15min, in addition to being
both sensitive and speciﬁc, the test could be an acceptable
alternative for use in clinical laboratories lacking specialized
equipment or the technological expertise needed for western
blotting or ELISA. Similarly, a new 3-minute rapid dot
immunogold ﬁltration assay (DIGFA) for serodiagnosis of
human CE and AE has been developed using four native
antigen preparations crude and partially puriﬁed hydatid
cyst ﬂuid extracts from E. granulosus (EgCF and AgB), E.
granulosus protoscolex extract (EgP), and E. multilocularis
metacestode antigen (Em2) [70]. Like the dipstick assay,
the test incorporates a simple eye-read colour change and
achieved an overall sensitivity of 80.7% for human CE and
92.9% for human AE in a hospital diagnostic setting [70].
These rapid test scan be used for both clinical diagnostic
support, as well as combining with ultrasound for mass
screening in areas endemic for CE and AE.
Standardizationoftechniquesandantigenicpreparations
and the characterization of new antigens are urgently
required to improve the performance of hydatid immunodi-
agnosis. Antigens used in current tests are either cyst ﬂuid or
crude homogenates of the parasite collected from domestic
animals. However, the supply of antigenic sources can often
be limited, even for laboratory use. Since the preparation
of puriﬁed echinococcal antigens relies on the availability
of parasitic material and the quality control of this material
is diﬃcult to standardize for a large scale production, this
can impact substantially on sensitivity and speciﬁcity of the
available immunodiagnostic tools.
3.2. Antigen Detection. Antibody detection is likely to indi-
cate exposure to an Echinococcus infection, but it may not
necessarily indicate the presence of an established and viable
infection, or the disease. Serum antibodies may persist for a
prolonged period, reaching up to 10 years after hydatid cyst
removal [84]. In addition, the degree of antibody response
may be related to the location and condition of a matureClinical and Developmental Immunology 5
Table 1: Characteristics of assays using diﬀerent antigens from E. granulosus developed after 2003 for immunodiagnosis of cystic
echinococcosis.
Number of subjects tested
Antigen Assay method Sensitivity (%) Speciﬁcity (%) Ig isotype Refs.
CE Healthy controls Other diseases
44 — 43 8kDa WB 47.7 51.2 IgG [67]
44 — 43 16kDa WB 45.5 67.4 IgG [67]
44 — 43 24kDa WB 68.2 62.8 IgG [67]
36 36 — AgB ELISA 91.7 97.2 IgG [68]
102 95 68 rAgB1 ELISA 88.2 80.9 IgG [69]
102 95 68 rAgB2 ELISA 91.2 93 IgG [69]
875 5 739 AgB Dot-WB 68.4 93.4 IgG [70]
857 5 739 AgB ELISA 57.4 93.4 IgG [70]
324 70 500 AB WB 86.4 92 IgG [71]
155 110 58 ? ELISA 73.6 99.1 IgE [72]
875 5 739 AgB Dot-WB 68.4 93.4 IgG [70]
857 5 739 AgB ELISA 57.4 93.4 IgG [70]
324 70 500 AB WB 86.4 92 IgG [71]
155 110 58 ? ELISA 73.6 99.1 IgE [72]
155 110 58 ? ELISA 90.3 90.9 IgG [72]
155 110 58 HCF WB 90.1 94.5 IgG [72]
324 70 500 EpC1 WB 88.7 95.6 IgG [71]
95 37 — HSP20 64 IgG1,4 [73]
97 37 58 Eg19 WB 10 100 IgG [74]
102 95 68 E14t ELISA 35.3 91.7 IgG [69]
102 95 68 C317 ELISA 58.8 80.9 IgG [69]
60 — — P5 WB 97 1 1 [75]
ELISA: enzyme-linked immunosorbent assay; WB: western blotting; dELISA: dot enzyme-linked immunosorbent assay.
hydatid cyst. For instance, hydatid cysts in human lung,
spleen, or kidney tend to be associated with lower serum
antibody levels [9]. Furthermore, in Echinococcus-endemic
villages, up to 26% or more of the general population may
have antibodies to HCF antigens, but with only about 2%
of the villagers having hydatid cysts [81, 85, 86], indicating
that the antibody levels may not necessarily reﬂect the true
prevalence of CE.
Antigen detection may provide a suitable alternative.
Serum antigen detection may also be less aﬀected by hydatid
cyst location and provides a tool for serological monitoring
of antiparasitic therapy [87]. Circulating antigen (CAg) in
CE patient sera, can be detected using ELISA directly or
indirectly, and against titrated cyst ﬂuid standards, CAg
concentrations have been shown to vary from 100 to
700ng/mL [88].
Antigen detection assays depend principally on the
binding of speciﬁc polyclonal or monoclonal antibodies to
parasite antigen present in serum or urine. A number of
diﬀerent assays have been developed to detect echinococcal
antigens. The standard double antibody sandwich ELISA
is a common method for measuring the presence and/or
concentration of circulating parasite antigens. In the test,
antibody raised to the targeted protein is coated onto a
microtiter plate to capture antigen (Figure 1). The same
antibody, which is enzyme labelled, is commonly used in
the tertiary layer of the assay. This type of antigen capture
therefore relies on the presence of multiple binding sites on
the target antigens(s). Eﬀorts to detect CAg in CE patients
have been reviewed extensively by Craig et al. [85].
CAg in serum is normally in the form of a circulating
immune complex (CIC) with some in free form. There-
fore, the serum needs to be treated with acid buﬀer or
polyethylene glycol (PEG) to release and concentrate the
circulating antigens. Acidic treatment (0.2M glycine/HCl)
of CE patient serum is quite straightforward to dissociate
CIC [85]. In a comparison of acid-treatment and PEG
precipitation methods, all the sera of 30 conﬁrmed positive
cases of CE had detectable levels of antigen in the acid-
treated sera [30]. However, 23 (77%) and 26 (87%) sera
of 30 conﬁrmed cases had free antigen as well as CIC of
an 8kDa antigen in the untreated and in the polyethylene
glycol (PEG) precipitated sera, respectively. None of the sera
fromotherpatientswithparasiticinfectionsorviralhepatitis
had any detectable levels of 8kDa antigen in the untreated,
acid-treated, or PEG-precipitated serum samples. These6 Clinical and Developmental Immunology
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PCR
PCR
First antibody Test antigen
(1) (2) (3) (4)
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Conjugate Substrate
Biotinylated antibody Streptavidin Biotinylated DNA Primers
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(c) (d)
(5)
Figure 1: Schematic of ELISA and immuno-PCR for detecting circulating antigen in serum. (a) Sandwich ELISA. (1) Plate is coated with
a capture antibody; (2) serum sample is added, and any antigen present in the serum binds to the capture antibody; (3) detecting antibody
conjugate is added and binds to the antigen; (4) substrate is added, and is converted by the enzyme to a detectable form. (b) Direct ELISA.
Plate is coated with diluted serum containing antigen; (2) detecting antibody is added, and binds to antigen; (3) enzyme-linked secondary
antibody is added, and binds to detecting antibody; (4) substrate is added and is converted by the enzyme to a detectable form. (c) Capture
immuno-PCR.(1)Plateiscoatedwithcaptureantibody;(2)serumsampleisadded;(3)biotinylateddetectingantibodyisaddedandbindsto
antigen; (4) Streptavidin and biotinylated reporter DNA are added, and the biotinylated antibody and biotinylated reporter DNA are linked
by streptavidin; (5) Primers and PCR components are added and PCR or real-time PCR undertaken to quantify antigen. (d) Non-capture
immuno-PCR. Serum sample is coated on the plate and the remainder of the steps are as for the capture-immuno-PCR (C).
investigations, therefore, suggested that the demonstration
of circulating antigen employing monospeciﬁc antibodies to
aﬃnity puriﬁed 8kDa antigen in acid-treated sera is more
eﬃcient than the detection of free circulating antigen or CIC
in untreated or in PEG-precipitated sera [89].
IgM CICs tend to be positively associated with active
hydatid disease [85, 90]. Combining measurement of circu-
lating antibody, CICs, and CAg resulted in an increase from
77% to 90% compared to measurement of serum antibody
alone [91]. Antigens in soluble CICs from CE patients have
been characterized by separating them on SDS-PAGE [85]o r
by ion-exchange fast protein liquid chromatography (FPLC)
[92]. Both studies indicated a candidate antigen detectable in
serum with an approximate relative molecular mass of 60–
67KDa, and which is also present in cyst ﬂuid.
Comparison of CAg and IgG antibody using ELISA,
together with western blotting, showed a relatively low
sensitivity (43%) for detection of speciﬁc serum antigen in
CE, compared to 75% for IgG antibodies [93]. However, the
speciﬁcity of this CAg ELISA was 90% when tested against
sera from AE patients and 100% against human cysticercosis
sera. The limited cross-reactivity may be a way for practical
diagnosis of CE in areas where AE and cysticercosis are
coendemic. The advantage of CAg detection is its high
sensitivity for detecting CE in 54–57% of patients who are
serumantibodynegative[91,93].CAgdetectiondoesappear,
therefore,tobepotentiallyusefulasasecondarytestforsome
suspected CE cases where antibody titers are low [85, 94].
A combination of CAg and antibody detection has
been shown to increase the sensitivity from 85% (antibody
only) to 89% (antibody+CAg) in ELISA of 115 surgically
conﬁrmed hydatid patients, 41 individuals exhibiting other
parasiticandunrelateddiseases,and69healthysubjects[95].
Although there has been no application to date for
echinococcal diagnosis, a technique for antigen detection,
called immunopolymerase chain reaction (immuno-PCR),
was developed by Sano et al. [96]. It combines the molecular
recognition of antibodies with the high DNA ampliﬁcation
capability of PCR. The procedure is similar to conventional
ELISA but is far more sensitive. And, in principle, could be
applied to the detection of single antigen molecules. Instead
of an enzyme, a DNA molecule is linked to the detection
antibody and serves as a template for PCR (Figure 1). The
DNAmoleculeisampliﬁedandthePCRproductismeasured
by gel electrophoresis. An improvement of this method is
to amplify the DNA fragment by real-time PCR, thereby
eliminating post-PCR analysis. Furthermore, real-time PCR
is extremely accurate and sensitive, which should make it
possible to quantitate very low amounts of DNA-coupled
detection antibody with high accuracy.
3.3. Serodiagnosis: The Future. Almost all available immun-
odiagnostic techniques, including methods for detecting
speciﬁc antibodies and circulating parasite antigens in serum
or other body ﬂuids, have been applied for diagnosing
echinococcosis. However, all the tools developed to date areClinical and Developmental Immunology 7
generally applicable for laboratory research purposes only.
None of the available diagnostic tools, kits, or methods are
generally accepted by clinical physicians. Nevertheless, such
serological tools are potentially important for epidemiolog-
ical studies, conﬁrmation of infection status, and treatment
and the monitoring of control programs, and eﬀorts should
continue so that new assays for improved, practical diagnosis
of echinococcosis are developed.
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